Name Development Level Target Family
Name Description
lenvatinib a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)
TCRDv5.2.0
DisGeNET
HPO
CTD_human
DrugCentral Indication
lenvatinib